Anticoagulants Market - By Drug Class (Factor Xa Inhibitors, Heparin, Warfarin, Direct Thrombin Inhibitors), By Route of Administration (Oral, Injectables), By Application (Venous Thromboembolism, Atrial Fibrillation), By Distribution Channel & Forecast, 2022-2030

Industry Overview

Anticoagulants Market size was more than USD 37 billion in 2021 and is projected to showcase over 9% CAGR between the forecast years 2022-2030. The rising prevalence of chronic disorders such as deep vein thrombosis and cardiovascular diseases (CVDs) is anticipated to boost the development of critical drugs and therapies.
 

To get more details on this report: Request Free Sample PDF
 

The incidence of chronic diseases is rising at an alarming rate across the globe. Factors such as obesity, unhealthy lifestyle habits, and extreme stress are contributing to the overall disease burden. Anticoagulants are used to prevent and treat blood clots in patients diagnosed with coronary artery disease (CAD), which can lead to heart attack or other serious complications.
 

According to a U.S. Centers for Disease Control & Prevention (CDC) report, coronary heart disease is among the most common type of heart ailments in the country, causing 382,820 deaths in 2020 alone. To prevent the adverse consequences of these diseases, the consumption of anticoagulants has increased. The prevalence of myocardial infection is also surging worldwide, with a significant portion of adults facing health issues due to stress and other instigating factors.
 

Possible side effects could hinder anticoagulants industry forecasts

Side-effects from anticoagulants or blood thinners may hinder the development of global anticoagulants market during the forecast timeline. The main side-effect of using these medicines is excessive bleeding. For instance, warfarin, an anticoagulant, possesses a higher risk of causing bleeding along with other side-effects, such as skin necrosis, blue or purple toe, congenital disabilities, and miscarriages. Most people with AFib, high blood pressure, and other issues are advised not to take anticoagulants to avoid complications.
 

Rising number of heart disease patients will fuel heparin demand

To get more details on this report: Request Free Sample PDF
 

The anticoagulants industry share is segmented into heparin, factor Xa inhibitor, warfarin, and direct thrombin inhibitor drugs. Heparin is a drug primarily used to prevent blood clot formation among various patients. Cardiac surgeons prescribe this blood thinner to treat a variety of health conditions, such as deep vein thrombosis, acute coronary syndrome, atrial fibrillation, and pulmonary embolism, unstable angina, among others. Global anticoagulants market share value from the heparin segment had crossed USD 4 billion during 2021.
 

Better bioavailability to augment oral anticoagulant usage

With respect to route of administration, the industry is divided into oral and injectable drugs. The global market share from the oral route segment was over USD 16 billion in 2021. Orally consumed drugs are one of the most common modes of administration. Direct oral anticoagulants (DOACs) have better bioavailability and minimal drug interaction. They are not affected by external elements, such as food and alcohol. A rise in the prevalence of stroke and systemic embolism among atrial fibrillation patients will augment the demand for oral anticoagulant medications.
 

Increasing prevalence of AFib will bolster the industry landscape

In terms of the applications, the atrial fibrillation/flutter management segment held more than 27% share of global anticoagulants market in 2021. The prevalence of AFib is increasing at a worrying rate. Public and private healthcare organizations worldwide are taking efforts to spread awareness regarding different heart conditions. According to the Stroke Association, U.K., more than 1 million people in the country are suffering from atrial fibrillation. Anticoagulants are being extensively used to treat this ailment.
 

High preference for drug purchase at hospital pharmacies

To get more details on this report: Request Free Sample PDF
 

The hospital pharmacy segment held over 53% share of anticoagulants market during 2021, with regards to distribution channel. Hospital pharmacies provide several benefits, such as easier availability of medicines. With advanced infrastructure and a greater number of medical professionals, a substantial portion of CVD patients visit hospital OPDs to avail treatment as well as drug prescriptions. As more patients prefer to get treatments at hospitals to benefit from high-quality care, anticoagulant sales across inhouse pharmacies will expand at a significant pace.
 

Surging geriatric population to drive Europe market trends

Europe anticoagulants market share is anticipated to exceed USD 13 billion by 2030. The pool of the elderly population is seeing a notable growth. According to the World Bank, Germany’s share of population aged 65 years and above stood at 21.98% in 2021. This factor has positively influenced the demand for anticoagulants. The demand for improvised and non-invasive treatments is rising among the regional geriatric population.
 

The region is also witnessing a healthy rise in new drug agreements between governments and healthcare organizations. For instance, in November 2021, the NHS England signed new agreements to scale up the production of direct oral anticoagulants (DOACs). These contracts would benefit more than 610,000 patients in the country over the next 3 years.
 

Product development strategies to fuel competitive landscape

Bristol-Myers Squibb, Bayer AG, Boehringer Ingelheim, Johnson and Johnson, Daiichi Sankyo Company, Amphastar Pharmaceuticals, Inc., Sanofi, Shenzhen Hepalink, Pfizer, Leo Pharma, Rovi, and United Therapeutics, are some of the leading drug companies in global anticoagulants market. These organizations are launching new products to enhance their competitive edge. For instance, in June 2021, Boehringer Ingelheim announced that its Pradaxa (dabigatran etexilate) oral tablets was granted the U.S. FDA’s approval to treat children aged between 3 months and 12 years old with venous thromboembolism (VTE). Similar strategies will enable the manufacturers to expand their global reach.
 

The impact of COVID-19 virus on anticoagulants market outlook

While there were supply chain disruptions due to lockdown policies in force, the COVID-19 pandemic seemed to have minimal impact on the global market growth. Evidently, a robust increase in venous thromboembolism (VTE) cases among COVID-19 patients was observed. The WHO, through its January 2021 report, declared that patients with COVID-19, both confirmed and suspected, must have access to follow-up care with low-dose anticoagulants. Such situations have spurred the consumption these drugs. Consistent rise in heart condition patients, however, will also lead to the introduction of more generic drugs, affecting the sale of products such as heparin from major producers to some extent.
 

The anticoagulants market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2030, for the following segments:

Click here to Buy Section of this Report

By Drug Category

• Heparins
• Factor Xa inhibitor
• Warfarin (Vitamin K antagonist)
• Direct thrombin inhibitor
• Others

By Route of Administration

• Oral
• Injectables

By Application

• Atrial Fibrillation/Flutter
• Venous Thromboembolism
• Coronary heart disease
• Others

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE